Nirogacestat
- Generic Name
- Nirogacestat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H41F2N5O
- CAS Number
- 1290543-63-3
- Unique Ingredient Identifier
- QZ62892OFJ
- Background
Nirogacestat has been used in trials studying the treatment of Breast Cancer, HIV Infection, Desmoid Tumors, Advanced Solid Tumors, and Aggressive Fibromatosis, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Cryoablation and Nirogacestat for Desmoid Tumor
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 23
- Registration Number
- NCT05949099
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT05879146
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Hellenic Society of Hematology
- Target Recruit Count
- 36
- Registration Number
- NCT05573802
- Locations
- 🇬🇷
General Hospital of Athens "Alexandra", NKUA, Therapeutic Clinic, Athens, Greece
🇬🇷Anticancer Hospital of Thessaloniki "Theageneio", Thessaloniki, Greece
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT05556798
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Nirogacestat in Ovarian Granulosa Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- SpringWorks Therapeutics, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT05348356
- Locations
- 🇺🇸
UCLA-JCCC Dept. of OBGYN - Women's Health Clinical Research Unit, Los Angeles, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- TeneoOne Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT05259839
- Locations
- 🇺🇸
University of Massachusetts - Worcester /ID# 243977, Worcester, Massachusetts, United States
🇺🇸University of Texas Southwestern Medical Center /ID# 243273, Dallas, Texas, United States
🇦🇺Fiona Stanley Hospital /ID# 244753, Murdoch, Western Australia, Australia
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 317
- Registration Number
- NCT05137054
- Locations
- 🇺🇸
Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 140
- Registration Number
- NCT04722146
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 35
- Registration Number
- NCT04195399
- Locations
- 🇺🇸
Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸UCSF Medical Center-Mission Bay, San Francisco, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Precision BioSciences, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04171843
- Locations
- 🇺🇸
MD Anderson, Houston, Texas, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.